Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › familial adenomatous polyposis

Familial adenomatous polyposis

Part of Microsatellite-stable colorectal cancer

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for familial adenomatous polyposis

7 trials tracked for familial adenomatous polyposis: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 71 citations.

7Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 4 Phase 1 1 Other / NA 1
  1. Phase 3 Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP) Completed · 71 cited
  2. Phase 2 Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer Completed
  3. Phase 2 Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers Completed
  4. Phase 2 Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis Completed
  5. Phase 2 Curcumin in Treating Patients With Familial Adenomatous Polyposis Completed
  6. Phase 1 Lyophilized Black Raspberries in Adults With Familial Adenomatous Polyposis (FAP) Completed
Show 1 more trials
  1. N/A Use of Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP) Completed

Showing the 7 most-cited and recently-updated of 7 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Familial adenomatous polyposis: what the trials found

Clinical trials have evaluated the efficacy of Celecoxib in patients with familial adenomatous polyposis. In a Phase 2 study, Celecoxib was administered to assess its impact on polyp burden 2.

A larger Phase 2 trial evaluating Celecoxib demonstrated a reduction in the number of polyps greater than or equal to 2mm in diameter within focal areas of the colorectum (ranging from -1% to -13%) and a significant decrease in global colorectal polyp burden by up to 40% 5.

Recent results — preliminary, needs further review

  • Erlotinib showed a mean reduction of 29.6% in duodenal polyp burden, though it resulted in no change in lower gastrointestinal polyp burden 3.
  • Black raspberry (BRB) slurry was associated with a statistically significant decrease in the burden of rectal polyps (p=0.043) and changes in apoptosis and cell proliferation (p=0.016) 6.
  • Curcumin was evaluated for its effect on polyp number and size, but no statistically significant differences were observed (p=0.58; p=0.76) 4.
  • Eflornithine did not show statistically significant improvements in investigator upper or lower GI assessments 1.

For the clinician treating this condition

  • Celecoxib has demonstrated a reduction in both focal and global colorectal polyp burden in patients with familial adenomatous polyposis.
  • Eflornithine did not demonstrate statistically significant improvements in GI assessments for this condition.

AI synthesis of 6 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Review of chemopreventive strategies for familial adenomatous polyposis including NSAIDs and other agents
Gastroenterology Sys. Review
Review of chemopreventive strategies for familial adenomatous polyposis including NSAIDs and other agents Review of chemoprevention options for familial adenomatous polyposis
This review evaluates chemopreventive strategies for familial adenomatous polyposis, including nonsteroidal anti-inflammatory drugs, prostag…
A review examined chemopreventive strategies for familial adenomatous polyposis, including NSAIDs and other agents, though specific results …
Frontiers May 19, 2026